Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 20 January 2026 - 22 January 2026

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

London, Jan 22, 2026, 09:13 GMT — Regular session GSK shares ticked up in early London trading Thursday as investors weighed the drugmaker’s push into a mid-stage food-allergy treatment alongside growing discussions over vaccine demand in the U.S. (London South East) The $2.2 billion cash offer for RAPT Therapeutics marks the company’s first major deal under CEO Luke Miels. It…
22 January 2026
····
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

New York, January 21, 2026, 14:11 EST — Regular session Pfizer shares gained roughly 0.8%, hitting $25.73 by Wednesday afternoon. The Health Care Select Sector SPDR ETF climbed around 1.2%, while the S&P 500 tracker SPY edged up about 0.5%. The move is modest, but investors are eager for clearer signals about Pfizer’s 2026 outlook after a rough patch for…
21 January 2026
······
AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play

AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play

New York, January 21, 2026, 12:40 EST — Regular session AbbVie Inc shares were up 88 cents, or about 0.4%, at $214.92 in midday trading on Wednesday, a muted move after a fresh round of analyst target changes. The stock has traded between $211.92 and $218.00, with about 5.3 million shares changing hands. It matters now because drugmakers are heading…
21 January 2026
····
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

New York, January 21, 2026, 05:35 ET — Premarket Shares of Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) dropped nearly 8%, slipping to $19.68 in premarket trading Wednesday. The decline follows the company’s announcement of an underwritten public offering worth $150 million in common stock and pre-funded warrants. These warrants let investors lock in shares now by paying most of the price…
21 January 2026
·····
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

New York, Jan 21, 2026, 04:20 EST — Premarket GSK plc’s U.S.-listed shares slipped 1.2% to $47.65 in light premarket trading Wednesday, following the announcement of a $2.2 billion acquisition and changes at its HIV joint venture. The RAPT Therapeutics acquisition marks the first big move by new CEO Luke Miels, coming as investors demand clearer plans from GSK on…
21 January 2026
·····
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Sydney, Jan 21, 2026, 17:33 AEDT — Markets have closed for the day. Telix Pharmaceuticals shares dropped 7.7% on Wednesday, settling at A$10.61. The decline came as investors digested a new quarterly update alongside a regulatory move in China related to its prostate cancer imaging business. (Google) This move is significant as Telix’s valuation remains heavily dependent on growth in…
21 January 2026
·····
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

New York, Jan 20, 2026, 19:13 ET — After-hours Corvus Pharmaceuticals shares surged over threefold on Tuesday following fresh data release on its experimental eczema pill. The biotech also announced plans to raise $150 million through an underwritten stock offering. After-hours trading saw the stock surge roughly 167% to $21.41, with about 84 million shares changing hands. This move matters…
21 January 2026
·····
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

New York, Jan 20, 2026, 15:50 EST — Regular session Gilead Sciences shares edged down 0.2% to $124.68 in afternoon trade, after swinging between $122.49 and $126.22 earlier. Bernstein SocGen Group held firm on its Outperform rating and $135 price target, pointing to Yeztugo as a major driver for Gilead’s 2026 forecast. The firm also flagged that the market may…
20 January 2026
···
Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

New York, January 20, 2026, 14:46 EST — During the regular session Pfizer (PFE) shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That…
20 January 2026
······
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

New York, January 20, 2026, 14:02 EST — Regular session Merck & Co (MRK.N) shares held steady on Tuesday following news that the company’s personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda (pembrolizumab). By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating…
20 January 2026
·····
AbbVie stock slips as traders watch Epkinly data and the next earnings clock

AbbVie stock slips as traders watch Epkinly data and the next earnings clock

New York, January 20, 2026, 13:13 ET — Regular session underway Shares of AbbVie Inc slipped 82 cents, or 0.4%, to $213.53 in early afternoon trading on Tuesday, fluctuating between $210.00 and $214.23. Around 2.9 million shares changed hands. The tick-by-tick move was modest, yet AbbVie’s shares have grown quick to respond to drug data. Investors are grappling with the…
20 January 2026
·····
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

New York, January 20, 2026, 11:21 EST — Regular session AstraZeneca PLC’s U.S.-listed shares fell Tuesday after the company revealed plans to pull its American depositary shares from Nasdaq and directly list ordinary shares on the New York Stock Exchange. The stock slid 4.4%, dropping to $90.23 in late morning trading. The switch swaps depositary-share wrappers for ordinary shares in…
20 January 2026
·····
1 2 3 … 45

Stock Market Today

  • Seadrill Shares Jump 8.9% on $235 Million Offshore Drilling Contracts
    January 22, 2026, 4:58 AM EST. Seadrill (SDRL) shares surged 8.9% to $38.16 after announcing new offshore drilling contracts worth $235 million, boosting its revenue backlog and earnings visibility through 2026-2027. Key deals include a $157 million drillship contract in Malaysia and a $78 million accommodation contract in Norway. Despite the optimism from contract wins, Seadrill's earnings per share (EPS) estimate for the upcoming quarter remains unchanged at $0.07, down 93.5% year-over-year. The stock carries a Zacks Rank #3 (Hold). Meanwhile, industry peer Helmerich & Payne rose 3.2% but holds a Zacks Rank #4 (Sell). Investors should watch for upcoming earnings revisions to gauge sustained momentum in Seadrill's shares.
Go toTop